Health condition
CIDP guide
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable immune neuropathy causing progressive weakness and numbness over months - distinguishing it from untreatable neuropathies is crucial.
Key points
What matters most, at a glance.
The essentials in plain English - symptoms, when to seek help, who to see and what treatment looks like.
-
Progressive or relapsing weakness and numbness in arms and legs evolving over more than eight weeks
-
Weakness affects proximal muscles too - difficulty with stairs and rising - unlike most other neuropathies
-
Diagnosis rests on nerve conduction studies showing demyelination, sometimes with CSF and MRI support
-
Treatments work: immunoglobulin, corticosteroids and plasma exchange are all evidence-based
-
Misdiagnosis is common in both directions - specialist review prevents both missed treatment and unnecessary immunotherapy
Understanding it
About CIDP guide, and what to do next.
CIDP is the chronic cousin of Guillain-Barré syndrome: an ongoing immune attack on peripheral nerve myelin producing weakness, numbness, imbalance and fatigue that build over months or relapse and remit. The pattern - weakness that includes hip and shoulder muscles, widespread reflex loss, relatively symmetric signs - separates it from the far commoner length-dependent neuropathies of diabetes or age, which do not respond to immunotherapy.
Because treatment is expensive and diagnosis imperfect, precision matters. Nerve conduction studies applying formal demyelination criteria are the backbone, supported where needed by cerebrospinal fluid protein, nerve root MRI and, increasingly, testing for nodal antibodies (contactin-1, NF155), which define variants needing different treatment such as rituximab. Standard CIDP responds to immunoglobulin or corticosteroids in the substantial majority, with response itself supporting the diagnosis; maintenance is then individualised and periodically re-challenged. If you have a progressive neuropathy labelled idiopathic - or a CIDP label that has never clearly responded to treatment - a review at a specialist peripheral nerve clinic is one of neurology’s highest-value second opinions.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them.
Frequently asked
Common questions about CIDP guide.
Quick, plain-English answers to what people ask us most.
-
What is CIDP?
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune condition in which the immune system attacks the protective myelin coating of peripheral nerves, causing progressive or relapsing weakness and sensory changes, typically affecting both sides of the body over a period of at least eight weeks. It is a treatable condition, and most people respond well to appropriate immune-modulating therapy. This overview covers the practical essentials for understanding and living with the condition.
-
What are the main symptoms to be aware of?
Key symptoms include gradually progressive or fluctuating limb weakness (often starting in the legs), numbness or tingling, reduced reflexes, fatigue, and balance difficulties related to sensory loss. Symptoms typically develop over weeks to months rather than the more rapid onset seen in some other nerve conditions. Recognising this gradual pattern is important for prompting timely diagnosis and treatment.
-
What treatment options are available?
The main treatment options are intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange, each working to reduce the abnormal immune attack on the nerves' myelin coating. Choice between these depends on individual factors including response, side effects, and practical considerations such as treatment logistics. Treatment often needs to be continued or repeated over time to maintain improvement and prevent relapse.
-
What does day-to-day life look like with CIDP?
With effective treatment, many people with CIDP regain significant strength and function, allowing a good quality of life, though some may have residual weakness or sensory changes requiring ongoing physiotherapy or adaptive strategies. Fatigue management and pacing activities can be helpful for many people. Regular specialist follow-up helps ensure treatment remains optimally effective as the condition evolves.
-
Will CIDP go into remission?
For some people, particularly with early, effective treatment, CIDP can go into long-term remission, sometimes allowing treatment to eventually be reduced or stopped under close specialist supervision. For others, it follows a more chronic, relapsing course requiring ongoing treatment. Your neurologist can give a more individualised outlook based on how your specific case has responded to treatment so far.
-
When should I see a specialist?
See a neurologist promptly if you notice progressive or fluctuating limb weakness, numbness or tingling developing over several weeks, as early diagnosis and treatment lead to better outcomes. NHS neurology referral can take several weeks; a private neurology consultation is typically available within about 2 weeks for earlier specialist assessment.